DOVER, N.H., March 18 ¡X TissueLink Medical Inc., a privately held medical device company, announced that they recently received FDA clearance for TissueLink„· technology which expands the pre-existing soft tissue indication to include the hemostatic sealing and coagulation of bone.
Dr. Victor Goldberg of The University Hospitals of Cleveland was one of the first orthopaedic surgeons to utilize TissueLink technology. Dr. Goldberg stated: ¡§Blood loss in orthopaedics occurs from both the soft and hard tissue. Bone bleeding in particular has been a problem as no technology has adequately controlled it. In the past we have focused on managing blood loss through strategies such as patient pre-operative donation and cell salvage. Now, TissueLink technology enables us to prevent blood loss. By preventing blood loss we may be able to reduce patient pre-donation requirements, decrease patient exposure to allogenic blood, and reduce post-operative pain, swelling, and hematoma formation. We are in the early stages of a formal clinical study focused on the use of TissueLink technology in arthroplasty"
For more information about this product -
http://www.tissuelink.com/
__________________
Mr. Jan B. Wade
Blood Management Consultant
Enhance Outcomes - Control Cost
For Information Call - 360 296-1807
Email
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
